Anadys Pharmaceuticals Announces Exercise of Underwriters' Over-Allotment Option.Business Editors/Health/Medical Writers BIOWIRE2K SAN DIEGO--(BUSINESS WIRE)--April 26, 2004 Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced that the underwriters of its initial public offering have exercised their over-allotment option to purchase an additional 743,950 shares of common stock. The proceeds to Anadys Pharmaceuticals, Inc., after deducting underwriting discounts, from the sale of these additional shares were approximately $4.8 million. This brings the total proceeds of the IPO (Initial Public Offering) The first time a company offers shares of stock to the public. While not a computer term per se, many founders, employees and insiders of computer companies have found this acronym more exciting than any tech term they ever heard. , before offering expenses and after deducting underwriting discounts and commissions, to $45,530,615. SG Cowen Securities Corporation acted as sole book-running manager, Piper Jaffray & Co. acted as co-lead manager, and Legg Mason Wood Walker, Incorporated and Needham & Company, Inc. acted as co-managers for the offering. Copies of the final prospectus Final Prospectus A legal document stating the price of a newly issued security, the delivery date, and other facts that are important for investors. Notes: The final prospectus must be given to every investor who purchases a new issue of registered securities. relating to Anadys' initial public offering may be obtained from either SG Cowen Securities Corporation Prospectus Department, 1221 Avenue of the Americas, 6th Floor, New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of , NY 10020 or through ADP (1) (Automatic Data Processing) Synonymous with data processing (DP), electronic data processing (EDP) and information processing. (2) (Automatic Data Processing, Inc., Roseland, NJ, www.adp. by a request faxed to 631-254-7268. A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on March 25, 2004. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Anadys Pharmaceuticals, Inc. Anadys Pharmaceuticals, Inc. is a biopharmaceutical company committed to advancing patient care by discovering, developing and commercializing novel small molecule, anti-infective medicines for the treatment of hepatitis C virus
Hepatitis B is a potentially serious form of liver inflammation due to infection by the hepatitis B virus (HBV). It occurs in both rapidly developing (acute) and long-lasting (chronic) forms, and is one of the most common chronic virus and bacterial infections. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion